Alzheimer and cardiovascular genetic scores and cognition: the FINGER randomized controlled trial
Gazi Saadmaan, Maria Carolina Dalmasso, Maleeha Maria, Jenni Lehtisalo, Mikko Hiltunen, Minna U Kaikkonen, Esko Levälahti, Francesca Mangialasche, et al.. Brain : a journal of neurology, 2026-02-07
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease and coronary artery disease are common late-life chronic conditions and share multiple risk factors, including the apolipoprotein E (APOE) ε4 allele. A meta-analysis of two multidomain lifestyle intervention trials found greater cognitive benefits in APOE4 carriers compared with non-carriers. This study investigated the impact of genetic risk scores for Alzheimer's disease and coronary artery disease (AD-GRS, CAD-GRS) on cognition in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) randomized controlled trial. FINGER included 1259 at-risk individuals without dementia from the general population, aged 60-77 years. Participants were randomized 1:1 to a 2-year multidomain lifestyle intervention or regular health advice. The primary outcome was change in cognition based on a modified Neuropsychological Test Battery (14 tests). Previous comprehensive AD-GRS and CAD-GRS were calculated using genome-wide association study data (1177 participants, with 585 in the control and 592 in the intervention groups, exploratory analysis). The intervention-control difference in annual overall cognition change (95% confidence interval) for participants with AD-GRS above/below the median (i.e. higher/lower risk) was 0.032 (0.002-0.063) versus 0.017 (-0.011 to 0.045), and for CAD-GRS above/below the median was 0.031 (0.002 to 0.059) versus 0.016 (-0.012 to 0.044). AD-GRS or CAD-GRS were not significantly related to the intervention effect overall (P > 0.46), but for AD-GRS there were differences between females and males (P = 0.024). The intervention-control difference in annual overall score change was 0.045 (0.004 to 0.087) for higher-risk females, 0.003 (-0.040 to 0.047) for lower-risk females, 0.019 (-0.026 to 0.064) for higher-risk males, and 0.027 (-0.009 to 0.064) for lower-risk males. People with genetic susceptibility for Alzheimer's disease/dementia or coronary artery disease can benefit from multidomain lifestyle interventions. Although the findings for the AD-GRS and CAD-GRS risk groups were similar to APOE4 carrier status, with additional gender differences for AD-GRS, these exploratory findings need to be verified across several multidomain lifestyle trials to ensure adequate statistical power and inclusion of genetically diverse populations.
What this study adds
Evidence grade: Moderate
The record lists 1,177 participants. In the FINGER trial, a two-year multidomain lifestyle intervention improved cognition slightly more in people with higher genetic risk scores for Alzheimer's disease or coronary artery disease. Its stated limit: Exploratory secondary analysis not powered for interactions; Finnish population only; subgroup findings need replication in other multidomain trials.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Saadmaan, G., Dalmasso, M. C., Maria, M., Lehtisalo, J., Hiltunen, M., Kaikkonen, M. U., et al. (2026). Alzheimer and cardiovascular genetic scores and cognition: the FINGER randomized controlled trial. Brain : a journal of neurology. https://doi.org/10.1093/brain/awaf277
Vancouver
Saadmaan G, Dalmasso MC, Maria M, Lehtisalo J, Hiltunen M, Kaikkonen MU, et al. Alzheimer and cardiovascular genetic scores and cognition: the FINGER randomized controlled trial. Brain : a journal of neurology. 2026. doi:10.1093/brain/awaf277. PMID: 40747850.
BibTeX
@article{saadmaan2026-40747850,
author = {Saadmaan, Gazi and Dalmasso, Maria Carolina and Maria, Maleeha and Lehtisalo, Jenni and Hiltunen, Mikko and Kaikkonen, Minna U and Levälahti, Esko and Mangialasche, Francesca and others},
title = {{Alzheimer and cardiovascular genetic scores and cognition: the FINGER randomized controlled trial}},
journal = {Brain : a journal of neurology},
year = {2026},
doi = {10.1093/brain/awaf277},
pmid = {40747850},
url = {https://doi.org/10.1093/brain/awaf277}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- A meta-analysis of two multidomain lifestyle intervention trials found greater cognitive benefits in APOE4 carriers compared with non-carriers.
- The intervention-control difference in annual overall cognition change (95% confidence interval) for participants with AD-GRS above/below the median (i.e. higher/lower risk) was 0.032 (0.002-0.063) versus 0.017 (-0.011 to 0.045), and for CAD-GRS above/below the median was 0.031 (0.002 to 0.059) versus 0.016 (-0.012 to 0.044).
- AD-GRS or CAD-GRS were not significantly related to the intervention effect overall (P > 0.46), but for AD-GRS there were differences between females and males (P = 0.024).
- The intervention-control difference in annual overall score change was 0.045 (0.004 to 0.087) for higher-risk females, 0.003 (-0.040 to 0.047) for lower-risk females, 0.019 (-0.026 to 0.064) for higher-risk males, and 0.027 (-0.009 to 0.064) for lower-risk males.
Why it matters
In the FINGER trial, a two-year multidomain lifestyle intervention improved cognition slightly more in people with higher genetic risk scores for Alzheimer's disease or coronary artery disease. The genetic risk scores themselves were not significantly related to cognition, and the analysis was exploratory.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designRCT
- Participants1,177
- Effect sizeIntervention-control difference in annual cognition change: 0.032 (95% CI 0.002-0.063) in higher AD-GRS vs 0.017 (-0.011 to 0.045) in lower AD-GRS
- Evidence strengthModerate
Limitations
Exploratory secondary analysis not powered for interactions; Finnish population only; subgroup findings need replication in other multidomain trials.
How this study scored 67/100
Published in a leading specialty journal, and it is a randomized controlled trial. We have no data on free to read, so that was left out: it earned 66 of the 98 points we could judge it on, which is 67 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Brain : a journal of neurology) |
| Journal's citation record | 4 / 4 | Brain: journal h-index 503 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,177 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 2 / 6 | Cited 1.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Alina Solomon: h-index 61 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Imperial College London: institution h-index 1,744 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 14 institution(s) in 6 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40747850) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 66 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 66 of the 98 points we could judge it on is 67 out of 100. |
| Total | 67 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Genetics from nearby years
Also in Genetics
201 studies in the library are filed under Genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Genetics hub.